Search Results - "Specenier, Pol"

A Review of the Most Promising Biomarkers in Colorectal Cancer: One Step Closer to Targeted Therapy by Deschoolmeester, Vanessa, Baay, Marc, Specenier, Pol, Lardon, Filip, Vermorken, Jan B.

“…Rapidly growing insights into the molecular biology of colorectal cancer (CRC) and recent developments in gene sequencing and molecular diagnostics have led to…”
Get full text

Anti‐Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance by Boeckx, Carolien, Baay, Marc, Wouters, An, Specenier, Pol, Vermorken, Jan B., Peeters, Marc, Lardon, Filip

“…Targeted therapy against the epidermal growth factor receptor (EGFR) is one of the most promising molecular therapeutics for head and neck squamous cell…”
Get full text

Current concepts for the management of head and neck cancer: Chemotherapy by Specenier, Pol M, Vermorken, Jan B

“…Summary Chemotherapy can be administered in patients with locoregionally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) either concurrently…”
Get full text

A Literature Review of the Potential Diagnostic Biomarkers of Head and Neck Neoplasms by Konings, Heleen, Stappers, Sofie, Geens, Margot, De Winter, Benedicte Y., Lamote, Kevin, van Meerbeeck, Jan P., Specenier, Pol, Vanderveken, Olivier M., Ledeganck, Kristien J.

“…Head and neck neoplasms have a poor prognosis because of their late diagnosis. Finding a biomarker to detect these tumors in an early phase could improve the…”
Get full text

Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins by Boeckx, Carolien, Op de Beeck, Ken, Wouters, An, Deschoolmeester, Vanessa, Limame, Ridha, Zwaenepoel, Karen, Specenier, Pol, Pauwels, Patrick, Vermorken, Jan B, Peeters, Marc, Van Camp, Guy, Baay, Marc, Lardon, Filip

“…Highlights • Gene expression profiles of cetuximab sensitive and resistant cells were compared. • Cetuximab resistant cells still exhibit RAS–MAPK signaling…”
Get full text

Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy by Geens, Margot, Stappers, Sofie, Konings, Heleen, De Winter, Benedicte Y, Specenier, Pol, Van Meerbeeck, Jan P, Verpooten, Gert A, Abrams, Steven, Janssens, Annelies, Peeters, Marc, Van de Heyning, Paul, Vanderveken, Olivier M, Ledeganck, Kristien J

“…In this study, we investigated serum epidermal growth factor (EGF) in an oncological population of head- and neck and pulmonary neoplasms and whether serum EGF…”
Get full text

Incidence of falls and fall-related injuries and their predictive factors in frail older persons with cancer: a multicenter study by Kenis, Cindy, Decoster, Lore, Flamaing, Johan, Debruyne, Philip R, De Groof, Inge, Focan, Christian, Cornélis, Frank, Verschaeve, Vincent, Bachmann, Christian, Bron, Dominique, Van den Bulck, Heidi, Schrijvers, Dirk, Langenaeken, Christine, Specenier, Pol, Jerusalem, Guy, Praet, Jean-Philippe, De Cock, Jessie, Lobelle, Jean-Pierre, Wildiers, Hans, Milisen, Koen

“…Abstract Background Falls and fall-related injuries are a major public health problem. Data on falls in older persons with cancer is limited and robust data on…”
Get full text

Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study by Helsen, Nils, Van den Wyngaert, Tim, Carp, Laurens, De Bree, Remco, VanderVeken, Olivier M., De Geeter, Frank, Maes, Alex, Cambier, Jean-Philippe, Spaepen, Karoline, Martens, Michel, Hakim, Sara, Beels, Laurence, Hoekstra, Otto S., Van den Weyngaert, Danielle, Stroobants, Sigrid, Van Laer, Carl, Specenier, Pol, Maes, Annelies, Debruyne, Philip, Hutsebaut, Isabel, Van Dinter, Joost, Homans, Filip, Goethals, Laurence, Lenssen, Oliver, Deben, Kristof

“…Background The Hopkins criteria were introduced for nodal response evaluation after therapy in head and neck cancer, but its superiority over quantification is…”
Get full text

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53 by Bossche, Jolien, Deben, Christophe, De Pauw, Ines, Lambrechts, Hilde, Hermans, Christophe, Deschoolmeester, Vanessa, Jacobs, Julie, Specenier, Pol, Pauwels, Patrick, Vermorken, Jan Baptist, Peeters, Marc, Lardon, Filip, Wouters, An

“…Polo‐like kinase 1 (Plk1), a master regulator of mitosis and the DNA damage response, is considered to be an intriguing target in the research field of mitotic…”
Get full text

Study protocol for a randomized controlled trial: prophylactic swallowing exercises in head-and-neck cancer patients treated with (chemo)radiotherapy (PRESTO trial) by Baudelet, Margot, Van den Steen, Leen, Duprez, Fréderic, De Bodt, Marc, Deschuymer, Sarah, Goeleven, Ann, Hutsebaut, Isabel, Mariën, Steven, Meersschout, Sabine, Nevens, Daan, Nuyts, Sandra, Peeters, Marc, Specenier, Pol, Van den Brekel, Michiel, van der Molen, Lisette, Vandenbruaene, Caroline, Vanderveken, Olivier, Van Dinther, Joost, Van Laer, Carl, Vauterin, Tom, Verstraete, Hilde, Van Nuffelen, Gwen

“…Dysphagia is a common and serious complication after (chemo)radiotherapy (CRT) for head-and-neck cancer (HNC) patients. Prophylactic swallowing exercises (PSE)…”
Get full text

Gemcitabine‐Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta‐Analysis by Vanderveken, Olivier M., Szturz, Petr, Specenier, Pol, Merlano, Marco C., Benasso, Marco, Van Gestel, Dirk, Wouters, Kristien, Van Laer, Carl, Van den Weyngaert, Danielle, Peeters, Marc, Vermorken, Jan

“…Background. Platinum‐based concurrent chemoradiation (CCRT) improves locoregional control and overall survival of locoregionally advanced (LA) squamous cell…”
Get full text

Cetuximab in the treatment of squamous cell carcinoma of the head and neck by Specenier, Pol, Vermorken, Jan B

“…The majority of the head and neck cancers are squamous cell carcinomas, which commonly overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal…”
Get full text

A rare case of primary mucosal melanoma involving the oropharynx by Bonte, Anne Sophie, Peetermans, Olivier, Sirimsi, Sabriya, Haesendonck, G. Van, Ocak, Ibrahim, Mariën, Steven, Specenier, Pol, Lambert, Julien, Vanderveken, Olivier

Get full text

Neoadjuvant chemotherapy in head and neck cancer: Should it be revisited? by Specenier, Pol M, Vermorken, Jan B

“…Abstract Locally advanced SCCHN (LA-SCCHN) is generally treated by a combination of chemotherapy, irradiation and/or surgery. Timing of the chemotherapy has…”
Get full text

Feasibility of tongue strength measurements during (chemo)radiotherapy in head and neck cancer patients by Van den Steen, Leen, Vanderveken, Olivier, Vanderwegen, Jan, Van Gestel, Dirk, Daisne, Jean-François, Allouche, Johan, Delacroix, Laurence, Van Rompaey, Diane, Beauvois, Sylvie, Cvilic, Sophie, Mariën, Steven, Desuter, Gauthier, Vermorken, Jan Baptist, Van den Weyngaert, Danielle, Specenier, Pol, Van Laer, Carl, Peeters, Marc, Van de Heyning, Paul, Chantrain, Gilbert, Lawson, Georges, Lazarus, Cathy, De Bodt, Marc, Van Nuffelen, Gwen

“…Purpose The aim of this study was to investigate the feasibility of tongue strength measures (TSMs) and the influence of bulb location, sex, and self-perceived…”
Get full text

Study protocol for a randomized controlled trial: tongue strengthening exercises in head and neck cancer patients, does exercise load matter? by Van Nuffelen, Gwen, Van den Steen, Leen, Vanderveken, Olivier, Specenier, Pol, Van Laer, Carl, Van Rompaey, Diane, Guns, Cindy, Mariën, Steven, Peeters, Marc, Van de Heyning, Paul, Vanderwegen, Jan, De Bodt, Marc

“…Reduced tongue strength is an important factor contributing to early and late dysphagia in head and neck cancer patients previously treated with…”
Get full text

Recurrent head and neck cancer: current treatment and future prospects by Specenier, Pol M, Vermorken, Jan B

“…Recurrent and metastatic squamous cell carcinoma of the head and neck still carries a poor prognosis. Response rates with combination chemotherapy regimens are…”
Get full text

EORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma by Lalami, Yassine, Specenier, Pol M, Awada, Ahmad, Lacombe, Denis, Liberatoscioli, Cecilia, Fortpied, Catherine, El-Hariry, Iman, Bogaerts, Jan, Andry, Guy, Langendijk, J.A, Vermorken, Jan B

“…Abstract Background: In this phase I/II study, the addition of lapatinib (LAP) was investigated in combination with the sequential use of both approaches TPF…”
Get full text

Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response by Boeckx, Carolien, Weyn, Christine, Vanden Bempt, Isabelle, Deschoolmeester, Vanessa, Wouters, An, Specenier, Pol, Van Laer, Carl, Van den Weyngaert, Danielle, Kockx, Mark, Vermorken, Jan B, Peeters, Marc, Pauwels, Patrick, Lardon, Filip, Baay, Marc

“…Targeted therapy against the Epidermal Growth Factor Receptor (EGFR) is among the most promising molecular therapeutics for Head and Neck Squamous Cell…”
Get full text

Programmed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus by Clotman, Katrien, Janssens, Katleen, Specenier, Pol, Weets, Ilse, De Block, Christophe E M

Get full text